Advertisement
UK markets closed

  • FTSE 100

    7,815.65
    -149.88 (-1.88%)
     

  • FTSE 250

    19,367.88
    -331.01 (-1.68%)
     

  • AIM

    739.63
    -10.65 (-1.42%)
     

  • GBP/EUR

    1.1700
    -0.0011 (-0.09%)
     

  • GBP/USD

    1.2433
    -0.0013 (-0.11%)
     

  • Bitcoin GBP

    49,918.91
    -2,002.10 (-3.86%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,057.15
    -4.67 (-0.09%)
     

  • DOW

    37,839.54
    +104.43 (+0.28%)
     

  • CRUDE OIL

    85.57
    +0.16 (+0.19%)
     

  • GOLD FUTURES

    2,399.10
    +16.10 (+0.68%)
     

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • DAX

    17,747.19
    -279.39 (-1.55%)
     

  • CAC 40

    7,920.78
    -124.33 (-1.55%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

Implied Volatility Surging for INSYS Therapeutics (INSY) Stock Options

Zacks Equity Research
Teladoc's (TDOC) Q1 earnings should benefit from increase in revenues, partly offset by rise in expenses.

Investors in INSYS Therapeutics, Inc. INSY need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 18, 2019 $6.00 Call had some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for INSYS Therapeutics shares, but what is the fundamental picture for the company? Currently, INSYS Therapeutics is a Zacks Rank #4 (Sell) in the Medical - Products industry that ranks in the Top 32% of our Zacks Industry Rank. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. The net effect has taken our Zacks Consensus Estimate for the current quarter from a loss of 7 cents per share to a loss of 13 cents per share in that period.

ADVERTISEMENT

Given the way analysts feel about INSYS Therapeutics book right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Looking to Trade Options?

Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the NFLXearnings report completely free. See it here: Bartosiak: Trading Netflix's (NFLX) Earnings with Optionsor check out the embedded video below for more details:


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Insys Therapeutics, Inc. (INSY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research